As the second most common male cancer in the world, roughly 1.3 million people receive a prostate cancer diagnosis each year. In its early stages, prostate cancer is highly treatable, but when advanced, effective treatments are limited. That’s where cancer immunotherapy offers new hope. There are already two FDA-approved immunotherapies—a therapeutic cancer vaccine and a checkpoint inhibitor—and many more promising treatments in clinical trials. Join Dr. Ana Aparicio of the University of Texas MD Anderson Cancer Center to discuss exciting scientific and clinical research. She’ll answer your questions about biomarkers and genomic sequencing, combination therapies, clinical trials, side effects, and more.